

## Press Release

29 August 2025 13:40:00 CEST

# CEO Nathaniel Hutley presents a strategic update on 2cureX's new Website Blog.

2cureX AB (Ticker: 2CUREX) today opens a News Blog on our website ([www.2curex.se](http://www.2curex.se)) with a strategic update on important developments in 2cureX and in the area of functional precision oncology.

The 2cureX Blog shares insights on IndiTreat® products, strategic developments at 2cureX, and broader topics related to functional precision oncology for cancer patients.

We'll post regularly and hope you enjoy this more informal approach. Suggestions are welcome at [ir@2curex.com](mailto:ir@2curex.com).

For more information about 2cureX:

---

Nathaniel Hutley, Interim CEO  
E-mail: [NH@2curex.com](mailto:NH@2curex.com)  
Telephone: +44 (776) 514 1346

## About 2cureX

---

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient's biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.

The first three IndiTreat® tests target patients with metastatic colorectal cancer:

- IndiTreat® Start (first-line therapy)
- IndiTreat® Extend & Explore (third-line options)

New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers. Despite global cancer IVD spending exceeding \$17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.

2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company's new commercial strategy, Operation Twin Code—now live.

## Attachments

---

[CEO Nathaniel Hutley presents a strategic update on 2cureX's new Website Blog.](#)